Oxidative stress (OS) is involved in several human diseases, including obesity, diabetes, atherosclerosis, carcinogenesis, as well as genetic diseases. We previously found that OS occurs in Down Syndrome as well as in Beckwith-Wiedemann Syndrome (BWS). Here we describe the clinical case of a female patient with Prader Willi Syndrome (PWS), a genomic imprinting disorder, characterized by obesity, atherosclerosis and diabetes mellitus type 2, pathologies in which a continuous and important production of free radicals takes place. We verified the presence of OS by measuring a redox biomarkers profile including total hydroperoxides (TH), non protein-bound iron (NPBI), thiols (SH), advanced oxidation protein products (AOPP) and isoprostanes. Thus we introduced in therapy an antioxidant agent, namely potassium ascorbate with ribose (PAR), in addition to GH therapy and we monitored the redox biomarkers profile for four years. A progressive decrease in OS biomarkers occurred until their normalization. In the meantime a weight loss was observed together with a steady growth in standards for age and sex.

Anichini, C., Lotti, F., Longini, M., Proietti, F., Felici, C., Perrone, S., et al. (2012). Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome. DISEASE MARKERS, 33(4), 179-183 [10.3233/DMA-2012-0922].

Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome

Anichini, Cecilia;Longini, Mariangela;Proietti, Fabrizio;Felici, Cosetta;Buonocore, Giuseppe
2012-01-01

Abstract

Oxidative stress (OS) is involved in several human diseases, including obesity, diabetes, atherosclerosis, carcinogenesis, as well as genetic diseases. We previously found that OS occurs in Down Syndrome as well as in Beckwith-Wiedemann Syndrome (BWS). Here we describe the clinical case of a female patient with Prader Willi Syndrome (PWS), a genomic imprinting disorder, characterized by obesity, atherosclerosis and diabetes mellitus type 2, pathologies in which a continuous and important production of free radicals takes place. We verified the presence of OS by measuring a redox biomarkers profile including total hydroperoxides (TH), non protein-bound iron (NPBI), thiols (SH), advanced oxidation protein products (AOPP) and isoprostanes. Thus we introduced in therapy an antioxidant agent, namely potassium ascorbate with ribose (PAR), in addition to GH therapy and we monitored the redox biomarkers profile for four years. A progressive decrease in OS biomarkers occurred until their normalization. In the meantime a weight loss was observed together with a steady growth in standards for age and sex.
2012
Anichini, C., Lotti, F., Longini, M., Proietti, F., Felici, C., Perrone, S., et al. (2012). Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome. DISEASE MARKERS, 33(4), 179-183 [10.3233/DMA-2012-0922].
File in questo prodotto:
File Dimensione Formato  
2012 Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome..pdf

accesso aperto

Descrizione: Articolo originale
Tipologia: PDF editoriale
Licenza: Creative commons
Dimensione 221.21 kB
Formato Adobe PDF
221.21 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/41845
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo